According to the terms of the deal, Novo Holdings would sell three of Catalent's factories, where injection pens are filled in sterile conditions, in Italy, Belgium and the United States ...

Specifically, Catalent's commercial cell therapy manufacturing facility in Princeton, New Jersey, will support manufacturing ...

The takeover also means that a related $11 billion transaction in which Novo Holdings' subsidiary Novo Nordisk takes control of three of Catalent’s fill-and-finish facilities in Italy ...

Novo Nordisk’s majority shareholder Novo Holdings is buying Catalent for $16.5 billion, and then selling the three fill-and-finish facilities in the US, Belgium, and Italy to Novo Nordisk for ...

The deal advances Galapagos' plan to develop a decentralized CAR T-cell therapy for non-Hodgkin lymphoma with a one-week vein-to-vein time.

Jan 16 (Reuters) - Novo Holdings, the controlling shareholder of Novo Nordisk (NOVOb.CO), opens new tab, hopes to double the size of its recently acquired contract drugmaker Catalent over five ...